



# Correlates of Durable Viral Suppression (DVS) Among Criminal Justice-involved (CJI) Black Men Living with HIV in Louisiana

Russell Brewer<sup>1,6</sup> · Rodal Issema<sup>1,6</sup> · Mary Moore<sup>2</sup> · Sarah Chrestman<sup>3</sup> · Snigdha Mukherjee<sup>4</sup> · Michelle Odlum<sup>5</sup> · John A. Schneider<sup>1,6</sup>

Published online: 27 June 2019  
© Springer Science+Business Media, LLC, part of Springer Nature 2019

## Abstract

Durable viral suppression (DVS) is needed to reduce HIV transmission risk and prevent new HIV infections. We examined changes in viral suppression and correlates of DVS among 97 criminal justice-involved (CJI) Black men living with HIV in Louisiana enrolled in a linkage, re-engagement, and retention in care intervention. Most participants (75%) were Black men who have sex with men. Forty-four percent (44%) were virally suppressed at baseline and only 20% had achieved DVS over a 12-month period. Multinomial logistic regression analyses showed that compared with DVS participants, those with no viral suppression (NVS) and some viral suppression (SVS) were more likely to have lived with HIV for a longer period of time and were less likely to be adherent at baseline. Medication adherence was critical for DVS among this sample of CJI Black men living with HIV who represent a high priority population for HIV care and treatment interventions.

**Keywords** Durable viral suppression · Black men who have sex with men (BMSM) · Criminal justice-involved · HIV · South

## Introduction

The National HIV/AIDS Strategy (NHAS) has described the need for persons living with HIV (PLWH) to access and be retained in HIV care in order to achieve viral suppression and improvements in overall health [1]. In addition, the Southern United States and criminal justice-involved (CJI) populations living with HIV are key priority jurisdictions and populations for HIV care and treatment interventions [1–5]. The post-release transition period is a vulnerable time for many CJI individuals living with HIV infection as the benefits of HIV treatment experienced during incarceration

are frequently lost upon community re-entry [2–5]. Post-release HIV care visits and medication adherence become challenging due to a variety of co-occurring factors including limited income, high levels of unemployment, HIV stigma, mental health issues, and relapse to drug and alcohol use [2–12]. Such barriers have also been noted among CJI Black men who have sex with men (BMSM) living with HIV infection [13, 14].

Louisiana has been described as “ground zero” for both HIV and incarceration given that the state has the third highest HIV diagnosis rate and highest incarceration rate in the United States [15–17]. An estimated 2.5% (500) of all PLWH are housed in Louisiana’s prisons, which is not inclusive of all PLWH in correctional settings [15, 18]. BMSM in particular are over-represented in correctional settings and experience a disproportionate burden of HIV [16, 19–22].

An examination of the correlates of durable viral suppression (DVS), a long-term indicator of sustained viral suppression among PLWH, has become an emerging and important area of HIV research [23–27]. Researchers contend that the most common measure of viral suppression in clinical and surveillance studies, the most recent viral load (VL) < 200 copies/mL in the last 12 months, is not a long-term indicator of viral suppression as it does not allow for VL dynamics or

✉ Russell Brewer  
rbrewer@medicine.bsd.uchicago.edu

<sup>1</sup> Department of Medicine, University of Chicago, Chicago, IL, USA  
<sup>2</sup> Dillard University, New Orleans, LA, USA  
<sup>3</sup> Louisiana Public Health Institute, New Orleans, LA, USA  
<sup>4</sup> Educational Commission for Foreign Graduates (ECFG), Philadelphia, PA, USA  
<sup>5</sup> Columbia University, New York, NY, USA  
<sup>6</sup> Chicago Center for HIV Elimination, Chicago, IL, USA

fluctuations over time. Persistent VL suppression, measured at multiple time points, can account for cumulative exposure to viral replication over time [23]. DVS is also necessary to prevent HIV transmission potential and new HIV infections [23–25].

Racial and ethnic differences in DVS have been observed among large representative samples of PLWH [23, 24]. Blacks are less likely to achieve DVS compared with their White and Hispanic counterparts living with HIV across a variety of subcategories including sex, age, and HIV risk group [23, 24]. The literature on the prevalence and correlates of DVS specifically among CJI Black men living with HIV who represent a high priority population is scant and studies in this area can inform future HIV care and treatment efforts for this population.

Strategies to enhance linkage, re-engagement, and retention in HIV care for CJI PLWH have included patient-centered approaches (e.g. case management and health navigation) focused on enhancing linkage and/or referrals to medical care and supportive services (e.g. substance abuse treatment, mental health services, housing placement, employment, health insurance support) [28–33]; the use of health information technology to facilitate access to HIV care (e.g. utilization of video conferencing between currently incarcerated individuals and case managers at Ryan White agencies) [34, 35]; and the use of health department staff dedicated to preventing treatment interruptions upon release [34]. What is less known about these approaches are their associations and long-term contributions to DVS among CJI Black men, particularly CJI BMSM living with HIV which is critical to improving their overall health, likelihood of HIV transmission, and preventing new HIV infections among a highly HIV impacted population.

The Louisiana Reentry Initiative (LRI) cohort intervention study was implemented from January 2013–February 2016, with a primary goal of linking, re-engaging, and retaining in HIV care, CJI PLWH in Louisiana. Three main patient-centered interventions (i.e. pre/post release case management, health navigation, and community outreach) were adapted and implemented to improve HIV outcomes among CJI PLWH. LRI was conducted in collaboration with six agencies from a variety of sectors (i.e. a community health center, two-community-based organizations, a local jail, state health department, and statewide public health institute) in two Louisiana cities (New Orleans and Baton Rouge) [33]. The primary aims of this exploratory analysis based on longitudinal data from the parent LRI study are to: (1) examine changes in viral suppression over time; and (2) identify the correlates of DVS over a 1-year period among CJI Black men living with HIV in Louisiana. We also describe differences between CJI BMSM and Black men who have sex with women (BMSW) in terms

of demographic, psychosocial, behavioral, health, and HIV outcomes.

## Methods

### Study Design

We conducted secondary data analysis from the parent LRI study which was a 3-year (i.e. 2013–2016) multi-city and multi-intervention cohort study. The inclusion criteria for participation in the parent LRI study included: (1) individuals with a confirmed HIV diagnosis, (2) persons with a history of incarceration (i.e. jail or prison) or current jail incarceration, (3) individuals living in or who intended to reside in the New Orleans or Baton Rouge metropolitan area post-incarceration, and (4) those who were at least 18 years of age. Participants may have consented to the study while in jail but the remaining study procedures (i.e. VLs, referrals to supportive services, medical appointment accompaniments) were completed post-release. One hundred and forty-four ( $n = 144$ ) individuals participated in the parent LRI study and completed a baseline intake assessment and VL test at enrollment or within the early stages of receiving one of the three patient-centered interventions. VL levels were measured at multiple time points (i.e. enrollment, 6-months, and 12-months post enrollment) and obtained from the Louisiana State Department of Health's HIV surveillance system. A preferred variability of  $\pm 1$  month was allowed for the 6 and 12-month follow-up periods. The patient-centered interventions were conducted over a 12-month period. LRI intervention components have been previously described [33]. Our analysis was restricted to 97 LRI participants who self-identified as a Black/African American male.

### Study Measures

#### Baseline Demographic Characteristics

The demographic characteristics assessed at enrollment included race/ethnicity, gender identity, sexual orientation, sexual partners within the last 6 months, age, annual income, education, relationship status, employment status, health insurance status, years living with HIV, and whether or not an individual was stably housed. The BMSM category included Black men who identified as gay, bisexual, and/or reported sex with other men. The BMSW category included Black men who identified as heterosexual or straight and only reported sex with women in the last 6 months.

## Baseline Psychosocial & Behavioral Characteristics

Incarceration-related characteristics—participants responded to a series of incarceration-related questions that assessed incarceration frequency in the last 6 months of at least 24 hours; duration of most recent incarceration; whether or not they were on parole or probation; whether or not someone picked them up from a correctional facility after their most recent release; and whether or not they received any HIV-related services (e.g. HIV testing, treatment, education) during their most recent incarceration.

HIV stigma—HIV stigma was assessed using a perceived stigma distancing scale [Cronbach alpha ( $\alpha$ )=0.803] which has been utilized in previous Louisiana studies among PLWH [3, 36]. Clients were read four stigma-related statements related to their HIV with responses ranging from “often” to “not at all” that measured how often they felt people avoided them, feared they would lose friends, thought people were uncomfortable being around them, and avoided obtaining treatment because someone might find out about their HIV status. Responses of “often” or “sometimes” were assigned one point and “not at all” or “rarely” were assigned zero points. These responses were summed and divided by four to create a final HIV stigma score with higher scores indicating greater levels of HIV stigma.

Social support—a six-item social support scale adapted from the Human Population Laboratory survey was used to assess levels of social support [37]. This scale has been utilized among large samples of BSM in the United States [20, 37]. The six items measured the availability of someone to talk to, availability of good advice about a problem, availability of love and affection, help with daily chores, emotional support, and level of contact with a trusted individual. Responses ranged from “none of the time” to “all of the time” and were assigned scores of one to four accordingly. These responses for each individual were summed to create a final social support score. Scores  $\geq 21$  were categorized as high levels of social support and scores  $< 21$  were categorized as moderate/low levels of social support ( $\alpha = 0.93$ ).

Depression—the Patient Health Questionnaire (PHQ-9) was used to assess depressive symptomatology within the past 2 weeks. This scale has been previously validated among racially and ethnically diverse patients ( $\alpha = 0.915$ ) [38]. Scores of zero to three were assigned to the response categories of “not at all” to “nearly every day”. Total scores ranging from 0 to 4, 5 to 9, 10 to 14, 15 to 19, and 20 to 27 represented minimal, mild, moderate, moderately severe and severe depression, respectively [38].

Any drug use—an adapted six-item drug use scale based on the Texas Christian University (TCU) Drug Screen II which has been validated among CJI populations was used to assess any drug use in the last month [39]. This scale measured the frequency with which participants used certain

drugs (e.g. crack, cocaine, heroin, crystal meth, etc.) in the last month. Scores of zero to four were assigned to response categories of “never”, “only a few times”, “1–3 times per month”, “1–5 times per week”, and “about every day”, respectively. Mean scores of zero were categorized as not using drugs while a mean score of one or more was categorized as any drug use.

## Baseline Health and HIV-related Characteristics

Any health care provider visit—participants indicated if they did or did not see a health care provider within the last 6 months.

Co-occurring health condition—participants responded to an open-ended question about whether or not they were ever diagnosed with another health condition such as a sexual transmitted infection (STI), diabetes, or high blood pressure.

Most urgent need—most urgent need was categorized as either a health care-related urgent need or an immediate urgent need. Health care-related needs consisted of dental services, drug and alcohol abuse treatment, HIV-related medical services, mental health services (inpatient or outpatient), non-HIV-related medical services, and pharmacy or medication services (for HIV or non-HIV reasons). Immediate urgent needs included employment, food or other subsistence needs, and housing or shelter. This measure was adapted from the Measurement Group, Missouri Department of Health and Senior Services, and the New York State Department of Health AIDS Institute [33].

Greatest barrier to HIV care—greatest barrier to HIV care consisted of three main categories: no barriers, individual-level barriers, and structural barriers. Participants who did not report any barriers to care at enrollment were classified as not having any barriers to care. Individual-level barriers consisted of denial, drug use, competing priorities, lack of money, lack of perceived need, stigma, and transportation. Structural barriers comprised homelessness, incarceration, and location of care. These measures were also adapted from the Measurement Group, Missouri Department of Health and Senior Services, and the New York State Department of Health AIDS Institute [33].

HIV medication self-efficacy—participants responded to an adapted measure based on the HIV Taking self-efficacy scale which has been validated among PLWH in the United States [40]. The modified 3-item scale measured the ability of participants to get their medications, take their medications, and attend their medical appointments ( $\alpha = 0.825$ ). Scores of one to five were assigned to responses of “strongly disagree” to “strongly agree” with higher scores indicating greater HIV medication self-efficacy.

HIV medication adherence—participants first responded to whether or not they were prescribed medications to treat their HIV. They then responded to five items to assess their

level of adherence. Participants who answered “Yes” to being prescribed medications for HIV treatment and identified as always taking their medication at the correct time were described as being adherent. Participants who either said they were not prescribed medications, skipped medications, took medication half the time, taking medication caused problems, or took medication less than half the time were defined as not being adherent [41].

## HIV Outcomes

**Baseline viral suppression**—baseline viral suppression was defined as having a VL of < 200 copies/milliliter (mL) at enrollment or within the early stages of receiving one of three patient-centered interventions. VL data was obtained from the Louisiana State Department of Health’s HIV surveillance system and later matched with each participant’s unique identifier.

**DVS**—three categories of viral suppression were assessed in the study: DVS, some viral suppression (SVS), and no viral suppression (NVS). DVS was defined as three VL values measured at baseline, 6, and 12- months post enrollment that were < 200 copies/mL. The SVS group consisted of participants with VL results of < 200 copies/mL at one or two data collection time points while participants in the NVS group did not have VL measures of < 200 copies/mL at any of the three data collection time points.

## Statistical Analyses

Descriptive analysis was performed and the sample was stratified into two groups: BMSM and BMSW. Given our interest in identifying differences between the two groups of Black men, chi square and Fisher’s exact tests were used to assess demographic, psychosocial, behavioral, health, and HIV outcomes. Variables were shortlisted for this analysis based on their importance in the literature (i.e. previous association with HIV care and treatment) and given our interest in exploring the incarceration-related covariates in order to inform future intervention studies [2, 3, 19, 20]. To address our goal of identifying the correlates of DVS, we conducted a multinomial logistic regression analysis by specifying two logit models to predict DVS as referent to NVS and SVS. Participants did not have to have all three VL measurements to be included in the analysis. Variables for the bivariate analysis were also shortlisted based on similar priorities already described. Bivariate multinomial analyses were conducted to shortlist variables for the multivariable multinomial models. All variables significantly associated with the outcome (level of significance  $\leq 0.10$ ) in the bivariate analysis were included in the multivariable model. Years living with HIV was included in the adjusted model a priori and enrollment city was excluded from the adjusted model

because it was closely correlated with the intervention type ( $r=0.95$ ). All multinomial analyses were run using robust calculations for the variance/covariance matrices, to limit the influence of potential outliers in the data. All analyses were performed using Stata 14.0 [42].

## Results

### Characteristics of Black Men Enrolled in the Study

Participant characteristics are described in Table 1. Nearly half of all participants either received the health navigation (47%) or pre/post release case management intervention (49%). The majority of participants were enrolled in Baton Rouge (53%); were BMSM (75%); were aged 30 or older (78%); reported limited income (90%) and education (88%). Most participants were not in a relationship (93%); did not have health insurance (64%); did not have a co-occurring health condition (59%); were living with HIV for 10 years or less (60%); and were stably housed (73%). In terms of employment status, 44% were unemployed and 30% were considered disabled/unable to work. The most common co-occurring conditions were (not included in Table 1): syphilis (19%), hepatitis (11%), depression (5%), diabetes (5%), and hypertension (5%).

Most participants had been incarcerated within the last 6 months (71%) with a length of stay of less than 6 months (54%). Most participants were not on parole or probation (62%); were not picked up by a family member, friend, or other person upon most recent release from a correctional facility (59%); and most reported receiving HIV-related services during their most recent incarceration (61%). The majority of participants reported low levels of stigma (53%) with a mean score of 0.27 [standard deviation (SD), 0.33]; high levels of social support (64%); minimal depressive symptoms (53%); a visit with a health care provider in the last 6 months (69%); non-health related immediate needs as urgent (51%); high levels of HIV medication self-efficacy (4.49, SD=0.70); and no drug use in the last month (73%). The most common types of drugs used included (not shown in Table 1): marijuana (22%), cocaine (4%), crack (3%), and prescription drugs (2%). More than a third of participants (38%) reported no barriers or individual-level barriers to HIV care. Fifty percent (50%,  $n=49$ ) of participants had completed three VL tests, 34% ( $n=33$ ) had completed two VL tests, and 15% ( $n=15$ ) had only completed only one VL test (not included in Table 1). The majority of participants were not virally suppressed at baseline (56%) and an even higher percentage of participants did not achieve DVS (80%) within a 12-month period even though most participants were prescribed HIV meds (68%) and were considered adherent (62%) at enrollment.

**Table 1** Sociodemographic and psychosocial characteristics among criminal justice-involved Black men living with HIV in Louisiana, Louisiana re-entry initiative 2013–2016 (n=97)

Participant characteristics	Total (n=97) n (%) <sup>a</sup>	BMSW (n=24) n (%) <sup>a</sup>	BMSM (n=73) n (%) <sup>a</sup>	p value
<b>Intervention</b>				
Health navigation	46 (47)	0 (0)	46 (63)	
Pre/post release CM	48 (49)	24 (100)	24 (33)	<0.001
Community outreach	3 (3)	0 (0)	3 (4)	
City (Baton Rouge)	51 (53)	0 (0)	46 (63)	<0.001
Age (30+)	76 (78)	22 (92)	54 (74)	0.09
Income (<\$20,000)	87 (90)	24 (100)	63 (86)	0.06
Education (≤High school or GED)	85 (88)	23 (96)	62 (85)	0.28
Not in a relationship	87 (93)	21 (88)	66 (94)	0.37
<b>Employed</b>				
No	42 (44)	11 (48)	31 (42)	
Yes	25 (26)	0 (0)	25 (34)	0.002
Disabled/unable to work	29 (30)	12 (52)	17 (23)	
Uninsured	62 (64)	16 (67)	46 (63)	0.75
Co-occurring health condition (No)	57 (59)	10 (42)	47 (64)	0.05
Years living with HIV (≤10 years)	58 (60)	10 (42)	48 (66)	0.04
Stable housing	71 (73)	16 (67)	55 (75)	0.41
Incarceration (last 6 months)	61 (71)	24 (100)	37 (60)	<0.001
Length of incarceration (<6 months)	51 (54)	11 (46)	40 (57)	0.34
Not on parole or probation	59 (62)	9 (38)	50 (70)	0.004
Picked up from correctional facility (No)	55 (59)	19 (79)	36 (51)	0.02
Received HIV services while incarcerated	59 (61)	23 (96)	36 (49)	<0.001
Stigma, mean (SD)	0.27 (0.33)	0.38 (0.32)	0.24 (0.33)	0.07
Social support (high)	62 (64)	13 (54)	49 (67)	0.25
<b>Depression</b>				
Minimal	51 (53)	9 (38)	42 (58)	
Mild	23 (24)	7 (29)	16 (22)	
Moderate/moderately severe	14 (14)	7 (29)	7 (10)	0.06
Severe	9 (9)	1 (4)	8 (11)	
Drug use (No)	71 (73)	23 (96)	48 (66)	0.003
Health care provider (last 6 months)	67 (69)	17 (71)	50 (68)	0.83
Most urgent needs (non-health-related)	49 (51)	13 (54)	36 (49)	0.68
<b>Greatest barriers</b>				
No barriers	37 (38)	8 (33)	29 (40)	
Individual	37 (38)	7 (29)	30 (41)	0.18
Structural	23 (24)	9 (38)	14 (19)	
HIV medication self-efficacy, mean (SD)	4.49 (0.70)	4.36 (0.51)	4.54 (0.76)	0.29
Baseline viral suppression (Yes)	43 (44)	13 (54)	30 (41)	0.26
<b>Durable viral suppression</b>				
NVS	36 (37)	6 (25)	30 (41)	
SVS	42 (43)	12 (50)	30 (41)	0.36
DVS	19 (20)	6 (25)	13 (18)	
Prescribed HIV meds (Yes)	65 (68)	18 (75)	47 (65)	0.38
HIV medication adherence (Yes)	60 (62)	14 (58)	46 (63)	0.68

CM case management

<sup>a</sup>May not sum to 100% due to rounding

## Comparing BMSW with BMSM Participants

Participant characteristics comparing BMSW with BMSM are described in Table 1. The majority of BMSM (63%) participants received the health navigation intervention whereas all (100%) BMSW received the pre/post release case management intervention ( $p < 0.001$ ). All (100%) BMSW participants were enrolled in New Orleans and the majority of BMSM participants (63%) were enrolled in Baton Rouge ( $p < 0.001$ ). Compared with BMSW, a greater proportion of BMSM were employed (34% vs. 0%,  $p = 0.002$ ); did not have a co-occurring health condition (64% vs. 42%,  $p = 0.05$ ); had been living with HIV for 10 years or less (66% vs. 42%,  $p = 0.04$ ); and were not on parole or probation (70% vs. 38%,  $p = 0.004$ ). Group differences in depression approached significance with a greater proportion of BMSM reporting minimal depressive symptoms compared with BMSW (58% vs. 38%,  $p = 0.06$ ).

Compared with BMSM, a greater proportion of BMSW had been incarcerated within the last 6 months (100% vs. 60%,  $p < 0.001$ ); were not picked up from a correctional facility post-release (79% vs. 51%,  $p = 0.02$ ); had received HIV services while incarcerated (96% vs. 49%,  $p < 0.001$ ); and reported no drug use (96% vs. 66%,  $p = 0.003$ ). Group differences in income levels approached significance with a greater proportion of BMSM reporting lower income levels compared with BMSM (100% vs. 86%,  $p = 0.06$ ). Higher proportions of BMSW were virally suppressed at baseline (54% vs. 41%) and had achieved DVS (25% vs. 18%) compared with BMSM but these differences were not statistically significant.

## Correlates of DVS Among Participants

The unadjusted and adjusted models with relative risk ratios (RRRs) are shown in Table 2 which compared the baseline correlates of DVS, NVS, and SVS among participants. Compared with the DVS group in the adjusted model, the NVS group was less likely to report a co-occurring health condition (aRRR = 0.12, 95% CI 0.02–0.91); more likely to have lived with HIV for a longer period of time (aRRR = 18.80, 95% CI 3.16–111.73); and less likely to be adherent at baseline (aRRR = 0.09, 95% CI 0.01–0.66). Group differences in age where the NVS group was less likely to be younger than the DVS group approached significance (aRRR = 0.01, 95% CI 0.01–1.10). Compared with the DVS group in the adjusted model, the SVS group was more likely to have lived with HIV for a longer period of time (aRRR = 7.0, 95% CI 1.29–37.70); less likely to have received HIV-related services during their most recent

incarceration (aRRR = 0.10, 95% CI 0.02–0.68); more likely to report severe depression (aRRR = 16.27, 95% CI 1.99–133.35); and less likely to be adherent at baseline (aRRR = 0.13, 95% CI 0.02–0.98).

## Discussion

The purpose of this exploratory study was not to examine intervention effects but rather to identify changes in viral suppression and the correlates of DVS among a CJI sample of Black men living with HIV. It is important to note that the LRI patient-centered interventionists provided individualized client-centered support (e.g. medical care accompaniments, referrals to supportive services) to enhance HIV linkage and retention in care. To the best of our knowledge, this is one of the first studies to examine the correlates of DVS among a CJI population living with HIV.

## Characteristics of CJI Black Men Enrolled in LRI

The majority of enrolled CJI Black male participants were BMSM with limited education, income, and health insurance which is consistent with the literature on the impact of incarceration among BMSM and low socio-economic and health insurance status among CJI populations in the United States [14, 19–21]. Overall, the current study found that the majority of CJI Black male participants reported low levels of stigma, high levels of social support, and minimal depressive symptoms. Few studies have documented and/or examine these characteristics among this population [43]. One-third of participants in our study did not report any barriers to HIV care at baseline. Such findings have been documented among previous samples of PLWH in Louisiana [3]. Participants may be unsure about and/or are still assessing their current HIV care barriers at enrollment. The majority of participants did not report any drug use in the last month which is contrary to previous studies which have shown higher levels of drug use among CJI BMSM populations prior to and post incarceration [14, 20, 44]. This is a high priority sample for HIV care and treatment interventions as most participants were not virally suppressed at baseline (56%) and had not achieved DVS (80%) over a 12-month period.

## Differences Between CJI BMSW and BMSM

Surprisingly, none of the BMSW participants were employed in the current study. This may be related to the high percentage of BMSW (52%) who were disabled/unable to work.

**Table 2** Results of estimated relative risk ratios (RRRs) (95% CI) of changes in viral suppression among criminal justice-involved Black men living with HIV in Louisiana, Louisiana re-entry initiative (n = 97), 2013–2016

Characteristics	DVS <sup>a</sup>			NVS <sup>b</sup> relative to DVS			SVS <sup>c</sup> relative to DVS		
	n (%)	n (%)	p value	Unadjusted	Adjusted <sup>d</sup>	p value	Unadjusted	Adjusted <sup>d</sup>	p value
<b>Intervention</b>									
Health navigation	5 (13)	19 (49)	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Pre/post release CM	11 (24)	13 (29)	0.27 (0.07, 0.92)	0.04	0.53 (0.03, 8.51)	0.66	0.48 (0.14, 1.63)	1.76 (0.12, 24.98)	0.68
Community outreach	2 (67)	0 (0)	–	–	–	–	0.13 (0.01, 1.79)	0.70 (0.02, 22.42)	0.84
<b>City</b>									
Baton Rouge	5 (11)	22 (48)	4.40 (1.29, 15.02)	0.02			2.31 (0.70, 7.64)		0.17
New Orleans	14 (27)	14 (27)	Ref				Ref		
<b>Age</b>									
< 30	1 (6)	12 (67)	Ref		Ref		Ref	Ref	
30 +	17 (25)	20 (29)	0.09 (0.01, 0.74)	0.03	0.10 (0.01, 1.10)	0.06	0.33 (0.04, 3.02)	0.55 (0.05, 6.13)	0.63
<b>Annual income (\$)</b>									
< 20,000	17 (22)	26 (33)	Ref				Ref		
≥ 20,000	1 (13)	6 (75)	5.14 (0.59, 45.17)	0.14			0.44 (0.03, 7.52)		0.57
<b>Education</b>									
≤ High school or GED	17 (20)	29 (34)	Ref				Ref		
> High school or GED	2 (17)	7 (58)	2.05 (0.38, 11.12)	0.41			0.65 (0.10, 4.32)		0.66
<b>Relationship</b>									
No	17 (20)	34 (39)	Ref				Ref		
Yes	0 (0)	2 (29)	–				–		
<b>Employed</b>									
No	10 (24)	16 (38)	Ref				Ref		
Yes	4 (16)	13 (52)	2.03 (0.51, 8.06)	0.31			1.25 (0.29, 5.30)		0.76
Disabled	5 (17)	7 (24)	0.87 (0.22, 3.55)	0.85			2.12 (0.59, 7.63)		0.25
<b>Health insurance</b>									
No	13 (21)	24 (39)	Ref				Ref		
Yes	6 (17)	12 (34)	1.08 (0.33, 3.58)	0.9			1.47 (0.47, 4.67)		0.51
<b>Co-occurring health condition</b>									
No	5 (10)	23 (46)	Ref		Ref		Ref	Ref	
Yes	13 (35)	9 (24)	0.16 (0.05, 0.55)	0.004	0.12 (0.02, 0.91)	0.04	0.20 (0.06, 0.66)	0.17 (0.03, 1.12)	0.07
<b>Years living with HIV</b>									
≤ 10 years	11 (22)	18 (37)	Ref		Ref		Ref	Ref	
> 10 years	7 (18)	14 (37)	1.09 (0.34, 3.46)	0.88	18.80 (3.16, 111.73)	0.001	1.29 (0.42, 3.94)	7.00 (1.29, 37.70)	0.02
<b>Housing status</b>									
No stable housing	8 (35)	6 (26)	Ref		Ref		Ref	Ref	
Stable housing	10 (16)	26 (41)	3.01 (0.88, 10.36)	0.08	4.98 (0.54, 45.83)	0.16	2.05 (0.65, 6.46)	6.14 (0.84, 45.09)	0.07



**Table 2** (continued)

Characteristics	DVS <sup>a</sup>			NVS <sup>b</sup> relative to DVS			SVS <sup>c</sup> relative to DVS			
	n (%)	n (%)	p value	Unadjusted	Adjusted <sup>d</sup>	p value	n (%)	Unadjusted	Adjusted <sup>d</sup>	p value
<b>Greatest barriers</b>										
No barriers	10 (28)	8 (25)	Ref	Ref	Ref	Ref	15 (47)	Ref	Ref	Ref
Individual	5 (15)	16 (47)	4.50 (1.15, 17.63)	4.20 (0.49, 35.94)	0.03	0.19	13 (38)	1.47 (0.41, 5.31)	2.12 (0.24, 18.38)	0.55
Structural	4 (19)	8 (38)	3.13 (0.70, 13.92)	6.05 (0.53, 69.08)	0.14	0.15	9 (43)	1.18 (0.29, 4.86)	3.08 (0.29, 32.67)	0.81
HIV medication self-efficacy, mean (SD)	4.70 (0.43)	4.27 (0.86)	0.31 (0.14, 0.69)	0.22 (0.03, 1.56)	0.004	0.13	4.65 (0.56)	0.79 (0.33, 1.87)	0.70 (0.11, 4.53)	0.59
<b>HIV medication adherence</b>										
No	1 (3)	16 (55)	Ref	Ref	Ref	Ref	12 (41)	Ref	Ref	Ref
Yes	17 (29)	16 (28)	0.04 (0.01, 0.37)	0.09 (0.01, 0.66)	0.004	0.02	25 (43)	0.09 (0.01, 0.75)	0.13 (0.02, 0.98)	0.03

CM case management

\*0.10 used as cut-off point for short-listing variables to adjusted model

<sup>a</sup>Durable viral suppression

<sup>b</sup>No viral suppression

<sup>c</sup>Some viral suppression

<sup>d</sup>Only participants without missing covariates data were included in the model (n = 87)

There were no observed statistically significant differences between BMSW and BMSM in terms of baseline viral suppression and DVS. This is contrary to the literature which has shown that MSM in general are more likely to achieve DVS compared with other transmission groups [23, 24].

**Changes in Viral Suppression and Correlates of DVS**

Correctional settings constitute an important setting for HIV care and treatment interventions as the receipt of HIV-related services during most recent incarceration was associated with DVS [2, 5, 6, 14]. In the current study, almost one-third (32%) of participants self-reported that they had not received a prescription for HIV medications at baseline which represents a missed opportunity. The observed changes in viral suppression (i.e. baseline suppression of 44% and DVS of 20%) are consistent with previous studies that have shown HIV care and treatment benefit loss upon community release [2–12]. As expected, medication adherence was critical for DVS such that participants who had achieved DVS were more likely to be adherent at baseline compared with both NVS and SVS participants. Participants who had achieved DVS were less likely to report severe depression compared with those who had achieved SVS. Previous studies have shown poor HIV outcomes among persons with a mental health condition [45, 46]. Even with the support of the patient-centered interventions, 80% of CJI Black male participants had not achieved DVS which may point to the need for more integrated and/or structural-focused strategies to support medication adherence and DVS among this sample of participants [47, 48].

We found an interesting association between the presence of a co-occurring health condition and DVS. Participants reporting a co-occurring health condition such as diabetes and hypertension were more likely to have achieved DVS compared with the NVS group. This finding is aligned with a growing body of research suggesting that greater frequency and contact with health service providers may provide secondary gains including greater opportunities for the diagnosis of a co-occurring health condition, health education, and treatment of a comorbid condition [49]. Compared with the DVS group, participants in the NVS and SVS group were more likely to have lived longer with HIV. This was a surprising finding and may point to treatment fatigue [50].

**Limitations and Other Considerations**

Our study findings should be considered within the context of several limitations. A major limitation of this analysis is the borderline sample size and associated wide confidence intervals. Our results should therefore be interpreted with caution. Given that this was an exploratory study and covariates were measured at one point in time (i.e. baseline),

inferences about causality cannot be made. Study findings are specific to CJI Black men and cannot be generalized to all CJI Black men living with HIV in the United States. The HIV stigma scale only included questions about the general public and did not include any questions related to negative experiences from correctional staff, health care providers, front-line staff, or supportive service providers. In addition, we did not assess intersectional stigma which are the perceived experiences and perceptions related to multiple identities (i.e. HIV stigma, sexual orientation, race, CJI background), and its impact on viral suppression and/or sustained viral suppression which is a barrier to medication adherence [51]. Participants did not have to have all three VL measurements to be included in the analysis. DVS was only measured over a period of a year in the current study compared with longer time-periods reported in previous studies [23, 24, 26, 27]. It is also unclear as to the actual contributions of the various interventions to DVS and/or how they may have impacted the findings. Additional research is needed in this area with a representative sample of CJI participants.

## Conclusions

Our study contributes to the HIV care continuum literature on the correlates of DVS among a CJI population living with HIV in a Deep South state. It highlighted changes in viral suppression, low levels of DVS, HIV medication prescription needs, and the continued importance of HIV adherence among this subset of participants.

**Acknowledgments** We would like to thank our study participants, intervention sites, and collaborators.

**Author's Contribution** All authors contributed to concept development. RB generated the manuscript outline and contributed to the initial and subsequent versions. MM, RI, and MO contributed to data cleaning, methods, analyses, and the results section. SC, SM, and JAS contributed to the introduction, results, and discussion section. In addition, RB served as PI for the study with SC and SM as Co-Investigators.

**Funding** This project was supported by a grant from AIDS United and the Corporation for National and Community Service (CNCS) with match funding provided by MAC AIDS Fund, Gilead Sciences, Inc., the Baton Rouge Area Foundation, and the Huey and Angelina Wilson Foundation. R. Brewer's time was also supported by a grant from NIMH (R25MH067127) for the Visiting Professor Program at the University of California, San Francisco; The Centers for Disease Control and Prevention's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (5U01PS005122-03); and NIDA (3P30DA027828-08S1).

## Compliance with Ethical Standards

**Conflict of interest** Dr. Russell Brewer currently serves as advisory to Gilead's Implementation Science Group and ViiV Healthcare's Accelerate Initiative.

**Ethical Approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional Review Board approval was obtained for the study.

**Informed Consent** Informed consent was obtained from all study participants.

## References

1. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020. Washington: the White House; July 2015. <https://www.whitehouse.gov/sites/whitehouse.gov/files/images/nhas-2016-progress-report.pdf>. Accessed 14 June 2018.
2. Harawa N, Brewer R, Buckman V, et al. HIV, sexually transmitted infection and substance use continuum of care interventions among criminal justice involved Black men who have sex with men: a systematic review. *Am J Public Health*. 2018;108(S4):e1–9. <https://doi.org/10.2105/AJPH.2018.304698>.
3. Brewer RA, Chrestman S, Mukherjee S, et al. Exploring the correlates of linkage to HIV medical care among persons living with HIV (PLWH) in the Deep South: lessons learned from the Louisiana Positive Charge Initiative. *AIDS Behav*. 2018. <https://doi.org/10.1007/s10461-018-2113-6>.
4. Chen NE, Meyer JP, Avery AK, et al. Adherence to HIV treatment and care among previously homeless jail detainees. *AIDS Behav*. 2013;17(8):2564–666.
5. Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. *Clin Infect Dis*. 2011;53(5):469–79.
6. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV infected prisoners: reincarceration and the lack of sustained benefit after release to the community. *Clin Infect Dis*. 2004;38:1754–60.
7. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. *J Am Med Assoc*. 2009;301(8):848–57. <https://doi.org/10.1001/jama.2009.202>.
8. Meyer JP, Cepeda J, Wu J, et al. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. *JAMA Intern Med*. 2014;174(5):721–9.
9. Dennis AC, Barrington C, Hino S, Gould M, Wohl D, Golin CE. “You're in a world of chaos”: experiences accessing HIV care and adhering to medications after incarceration. *J Assoc Nurses AIDS Care*. 2015;26(5):542–55.
10. Zelenev A, Marcus R, Kopelev A, et al. Patterns of homelessness and implications for HIV health after release from jail. *AIDS Behav*. 2013;17(Suppl 2):S181–94.
11. Rozanova J, Brown SE, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. *Health Justice*. 2015;18(3):18.
12. Kemnitz R, Kuehl TC, Hochstatter KR, et al. Manifestations of HIV stigma and their impact on retention in care for people

- transitioning from prisons to communities. *Health Justice*. 2017. <https://doi.org/10.1186/s40352-017-0054-1>.
13. Vagenas P, Zelenev A, Altice FL, et al. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. *AIDS Care*. 2016;28(1):22–31.
  14. Schneider JA, Kozloski M, Michaels S, et al. Criminal justice involvement history is associated with better HIV care continuum metrics among a population-based sample of young black MSM. *AIDS*. 2017;31:159–65.
  15. Human Rights Watch. Paying the price. Failure to deliver HIV services in Louisiana Parish Jails. 2016. <https://www.hrw.org/report/2016/03/29/paying-price/failure-deliver-hiv-services-louisiana-parish-jails>. Accessed 11 March 2017.
  16. State of Louisiana Department of Health, Office of Public Health. 2016 STD/HIV Program Report. [http://www.ldh.la.gov/assets/oph/HIVSTD/std/STDAnnualReports/2016\\_STDHIV\\_SurveillanceReport\\_Final.pdf](http://www.ldh.la.gov/assets/oph/HIVSTD/std/STDAnnualReports/2016_STDHIV_SurveillanceReport_Final.pdf). Accessed 14 June 2018.
  17. Hinds O, Kang-Brown J, Lu O.: People in Prison on 2017. [https://storage.googleapis.com/vera-web-assets/downloads/Publications/people-in-prison-2017/legacy\\_downloads/people-in-prison-2017.pdf](https://storage.googleapis.com/vera-web-assets/downloads/Publications/people-in-prison-2017/legacy_downloads/people-in-prison-2017.pdf). Accessed 14 June 2018.
  18. ACE TA Center. Connecting recently incarcerated people living with HIV to health coverage and care. [https://careacttarget.org/sites/default/files/supporting-files/ACE\\_Connecting\\_Recently\\_Incarcerated\\_PLWH\\_Health\\_Coverage\\_June2016.pdf](https://careacttarget.org/sites/default/files/supporting-files/ACE_Connecting_Recently_Incarcerated_PLWH_Health_Coverage_June2016.pdf). Accessed 14 June 2018.
  19. Brewer RA, Magnus M, Kuo I, et al. Exploring the relationship between incarceration and HIV among black men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2014;65(2):218–25.
  20. Brewer RA, Magnus M, Kuo I, et al. The high prevalence of incarceration history among Black men who have sex with men in the United States: associations and implications. *Am J Public Health*. 2014;104(3):448–54.
  21. Meyer IH, Flores AR, Stemple L, et al. Incarceration rates and traits of sexual minorities in the United States: national inmate survey, 2011–2012. *Am J Public Health*. 2017;107(2):267–73.
  22. Centers for Disease Control and Prevention. HIV in the United States: At a glance. 2017. <https://www.cdc.gov/hiv/pdf/statistics/overview/cdc-hiv-us-ataglance.pdf>. Accessed 14 June 2018.
  23. Crepaz N, Tang T, Marks G, Mugavero MJ, Espinoza L, Hall HI. Durable viral suppression and transmission risk potential among persons with diagnosed HIV infection: United States, 2012–2013. *Clin Infect Dis*. 2016;63:976–83.
  24. Crepaz N, Dong X, Wang X, Hernandez AL, Hall HI. Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care- United States, 2014. *MMWR*. 2018;67(4):113–8.
  25. Crawford TN, Thornton A. Retention in continuous care and sustained viral suppression: examining the association among individuals living with HIV. *J Int Assoc Providers AIDS Care*. 2017;16(1):42–7.
  26. Jefferson KA, Kersanske LS, Wolfe ME, et al. Place-based predictors of HIV viral suppression and durable suppression among men who have sex with men in New York city. *AIDS Behav*. 2017;21:2987–99.
  27. Wood SM, Lowenthal E, Lee S, Ratcliffe SJ, Dowshen N. Longitudinal viral suppression among a cohort of adolescents and young adults with behaviorally acquired human immunodeficiency virus. *AIDS Patient Care STDs*. 2017;31:377–83.
  28. Spaulding AC, Booker CA, Freeman SH, et al. Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. *AIDS Behav*. 2013;17:S100–7.
  29. Zaller ND, Holmes L, Dyl AC, et al. Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge. *J Health Care Poor Underserved*. 2008;19:522–31.
  30. Kim JJ, Maulsby C, Kinsky S, et al. The development and implementation of the national evaluation strategy of access to care, a multi-site linkage to care initiative in the United States. *AIDS Educ Prev*. 2014;26:429–44.
  31. Jain KM, Holtgrave DR, Maulsby C, et al. Improving access to HIV care: lessons from 5 US sites. Baltimore: Johns Hopkins University Press; 2016.
  32. Brewer RA, Chrestman S, Mukherjee S, et al. Exploring the correlates of linkage to HIV medical care among persons living with HIV (PLWH) in the Deep South: lessons learned from the Louisiana Positive Charge Initiative. *AIDS Behav*. 2018. <https://doi.org/10.1007/s10461-018-2113-6>.
  33. Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. *AIDS Educ Prev*. 2017;29(5):443–56.
  34. Brantley AD, Page KM, Zack B, et al. Making the connection: using videoconferencing to increase linkage to care for incarcerated persons living with HIV post-release. *AIDS Behav*. 2018. <https://doi.org/10.1007/s10461-018-2115-4>.
  35. Butler B, Murphy J. The impact of policies promoting health information technology on health care delivery in jails and local communities. *Health Aff*. 2014;33:487–92.
  36. Sowell RL, Lowenstein A, Moneyham L, et al. Resources, stigma, and patterns of disclosure in rural women with HIV infection. *Public Health Nurs*. 1997;14(5):302–12.
  37. Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. *PLoS ONE*. 2013;8(7):e70413.
  38. Huang FY, Chung H, Kroenke K, et al. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. *J Gen Intern Med*. 2006;21(6):547–52.
  39. Peters RH, Greenbaum PE, Steinberg ML, et al. Effectiveness of screening instruments in detecting substance use disorders among prisoners. *J Subst Abuse Treat*. 2000;18(4):349–58.
  40. Erlen JA, Cha E, Kim KH, et al. The HIV medication taking self-efficacy scale: psychometric evaluation. *J Adv Nurs*. 2010;66(11):2560–72.
  41. Southwest Louisiana AIDS Council (SLAC). HIV adherence treatment form. <https://www.slac.org/>. Accessed 14 June 2018.
  42. StataCorp. Stata statistical software: release 14. College Station: StataCorp LP; 2015.
  43. Beckwith C, Castonguay BU, Trezza C, et al. Gender difference in HIV care among criminal justice-involved persons: baseline data from the CARE+ corrections study. *PLoS ONE*. 2017;12(1):e0169078. <https://doi.org/10.1371/journal.pone.0169078>.
  44. Schneider JA, Lancki N, Schumm P. At the intersection of criminal justice involvement and sexual orientation: dynamic networks and health among a population-based sample of young Black men who have sex with men. *Social Networks*. 2017;51:73–87.
  45. Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. *AIDS Care*. 2009;21(5):655–63.
  46. Yehia BR, Stephens-Shield AJ, Momplaisir F, et al. Health outcomes of HIV-infected people with mental illness. *AIDS Behav*. 2015;19(8):1491–500.
  47. Chuah FLH, Haldane VE, Cervero-Liceras F, et al. Interventions and approaches to integrating HIV and mental health services: a systematic review. *Health Policy Plan*. 2017;32(Suppl 4):iv27–47.

48. Brewer R, Daunis C, Ebaady S, et al. Implementation of a socio-structural demonstration project to improve HIV outcomes among young Black men in the Deep South. *J Racial Ethn Health Disparities*. 2019. <https://doi.org/10.1007/s40615-019-00576-x>.
49. Manne-Goehler J, Siedner MJ, Montana L, et al. Hypertension and diabetes control along the HIV care cascade in rural South Africa. *JIAS*. 2019;22(3):e25213. <https://doi.org/10.1002/jia2.25213>.
50. Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. *Psychol Health Med*. 2015;20(3):255–65.
51. Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Longitudinal relationships between antiretroviral treatment adherence and discrimination due to HIV-serostatus, race, and sexual orientation among African-American men with HIV. *Ann Behav Med*. 2010;40:184–90.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.